Oragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26

Oragenics (OGEN) activated a third clinical site in Australia for its Phase 2a trial of ONP-002 to treat mild traumatic brain injury (mTBI)/concussion. The update is a modest positive step toward trial execution, but no efficacy, dosing, or timeline results were provided, limiting expected near-term market impact.

Analysis

Oragenics (OGEN) activated a third clinical site in Australia for its Phase 2a trial of ONP-002 to treat mild traumatic brain injury (mTBI)/concussion. The update is a modest positive step toward trial execution, but no efficacy, dosing, or timeline results were provided, limiting expected near-term market impact.